Home > Blog > Full service phase ii cancer trial

1 min read

Successful Full-Service, Randomized Pancreatic Cancer Phase II Trial

Success Stories Oncology Biologics Full-Service

Learn how Veristat’s multidisciplinary team was able to work with the sponsor to solve challenges across numerous areas of this full-service phase II cancer trial. Collaborative efforts led to the sponsor decided not to close the Phase II study upon the recommendation of the Safety Review Committee since the primary endpoint was met and there were no safety concerns.

A clinical-stage biopharmaceutical company approached Veristat in a multi-center, randomized Phase II study of a modified synthetic peptide in patients with exocrine pancreatic cancer. The study aimed to establish the efficacy and safety of combinations of the therapy in patients with stage IV exocrine pancreatic cancer. 

In this piece, learn how Veristat’s multidisciplinary team was able to work with the sponsor to solve challenges across numerous areas including: 
  • Slow recruitment
  • Data cleansing post-MSU
  • Multi-site location, process, and staffing
DOWNLOAD

 

Meet Veristat. Learn More.


 

1 min read

SCOPE: Powering the Future of Clinical Research

Nov 20, 2025  Veristat Events

Meet Veristat at SCOPE: Powering the Future of Clinical Research February 2-5, 2026

🔬 Advancing Clinical Research with...

1 min read

ASH Annual Meeting and Exposition

Oct 22, 2025  Veristat Events

Meet Veristat at ASH Meeting and Exposition December 6-9, 2025

Veristat is excited to attend the ASH Annual Meeting and...